Company Analysis

Immunome, Inc. (IMNM)

Nasdaq: IMNM · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2009
Grade5.1
◀ Past 3.2● Present 5.0▶ Future 6.5
3 est.

Who runs Immunome, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Siegall Clay B
President and CEO. First filing Oct 2023, latest Jul 27, 2026, 9 filings in all.
Officers reporting now
7
of 13 people with a filing in the last fifteen months
Directors reporting now
6
29 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Higgins JackChief Scientific OfficerOct 2023Sep 15, 20262 · $500,000
Horn KinneyCHIEF BUSINESS OFFICERFeb 2024Aug 6, 20262 · $2.3M
Siegall Clay BPresident and CEOOct 2023Jul 27, 2026none
Rosett MaxChief Financial OfficerOct 2023Jul 27, 20263 · $2.5M
Lechleider RobertChief Medical OfficerOct 2023Jul 27, 20265 · $2.3M
Stoneman Sandra G.CHIEF LEGAL OFFICER & GCNov 2020Jul 27, 2026none
Tsai PhilipChief Technical OfficerJun 2024Jul 27, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Barchas IsaacdirectorOct 2023Aug 12, 202612 · $18.3M
Bienaime Jean JacquesdirectorNov 2023Jun 12, 20262 · $200,000
Boylan James PdirectorOct 2023Jun 12, 2026none
Schafer CaroldirectorJan 2024Jun 12, 2026none
Swain Sandra MdirectorApr 2024Jun 12, 2026none
Wagenheim PhilipdirectorOct 2020Jun 12, 20262 · $1.3M
Earlier names on the record17, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IMNM · research, not advice